Drug Trial Radar · NCT04489888
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Oct 27, 2020
Primary completion
Feb 20, 2023
Study completion Jun 28, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.
Conditions
- Squamous Cell Carcinoma of Head and Neck
Interventions
PembrolizumabDrug
Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
CarboplatinDrug
Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
PaclitaxelDrug
At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to ~25 months
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
Yale-New Haven Hospital-Yale Cancer Center ( Site 0265)
New Haven, Connecticut
Helen F. Graham Cancer Center & Research Institute ( Site 0214)
Newark, Delaware
Baptist MD Anderson Cancer Center ( Site 0215)
Jacksonville, Florida
Orlando Health, Inc. ( Site 0216)
Orlando, Florida
Regions Hospital ( Site 0227)
Saint Paul, Minnesota
Washington University School of Medicine ( Site 0240)
St Louis, Missouri
Erie County Medical Center-Head & Neck Surgery and Plastic & Reconstructive Surgery ( Site 0268)
Buffalo, New York
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262)
Mineola, New York
Novant Health Presbyterian ( Site 0261)
Charlotte, North Carolina
Novant Health Forsyth Medical Center ( Site 0266)
Winston-Salem, North Carolina
UPMC Hillman Cancer Center ( Site 0253)
Pittsburgh, Pennsylvania
Abington Hospital - Asplundh Cancer Center ( Site 0229)
Willow Grove, Pennsylvania
Charleston Oncology ( Site 0231)
Charleston, South Carolina
Virginia Commonwealth University ( Site 0233)
Richmond, Virginia
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0303)
Buenos Aires, Argentina
Fundación Respirar ( Site 0306)
Buenos Aires, Argentina
Instituto Medico Especializado Alexander Fleming ( Site 0301)
Buenos Aires, Argentina
Hospital Provincial del Centenario ( Site 0304)
Rosario, Santa Fe Province, Argentina
Centro Medico San Roque ( Site 0302)
San Miguel de Tucumán, Tucumán Province, Argentina
Orange Health Services ( Site 0106)
Orange, New South Wales, Australia
The Townsville Hospital ( Site 0105)
Douglas, Queensland, Australia
Gold Coast University Hospital ( Site 0103)
Southport, Queensland, Australia
St Vincents Hospital Melbourne ( Site 0101)
Fitzroy, Victoria, Australia
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0402)
São Paulo, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0401)
São Paulo, Brazil
A.C. Camargo Cancer Center ( Site 0405)
São Paulo, Brazil
Centro Regional Integrado de Oncologia ( Site 0403)
Fortaleza, Ceará, Brazil
CETUS Hospital Dia Oncologia ( Site 0400)
Belo Horizonte, Minas Gerais, Brazil
Liga Norte Riograndense Contra o Cancer ( Site 0404)
Natal, Rio Grande do Norte, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0406)
Ijuí, Rio Grande do Sul, Brazil
Tom Baker Cancer Center ( Site 0014)
Calgary, Alberta, Canada
Dr. H. Bliss Murphy Cancer Centre ( Site 0001)
St. John's, Newfoundland and Labrador, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital ( Site 0004)
Kingston, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0005)
Toronto, Ontario, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0003)
Sherbrooke, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.